17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

Contemporary Canadian pharmacy practice is embedded within complex healthcare systems requiring seamless interprofessional teamwork, intra-professional delegation, and resource stewardship. Pharmacists interact daily with physicians, nurse practitioners, registered nurses, and allied healthcare professionals to optimize patient care. Concurrently, pharmacists lead dispensary workflow optimization by collaborating with Registered Pharmacy Technicians (RPhTs), navigate national drug supply vulnerabilities, and spearhead formulary modernization through biosimilar switching initiatives.

---

Principles of Interprofessional Collaboration & Structured Communication

The Canadian Interprofessional Health Collaborative (CIHC) defines interprofessional collaboration as a partnership between a team of health professionals and a patient in a participatory, collaborative, and coordinated approach to shared decision-making around health issues. The CIHC National Interprofessional Competency Framework identifies six core competencies:

1. Role Clarification: Understanding one's own professional role and the roles of other healthcare providers;
2. Team Functioning: Fostering shared values, mutual respect, and collaborative dynamics;
3. Patient/Client/Family-Centered Care: Actively engaging the patient as an equal partner in decision-making;
4. Collaborative Leadership: Shared accountability where leadership shifts based on clinical expertise and patient needs;
5. Interprofessional Conflict Resolution: Proactively managing differing professional opinions through consensus;
6. Interprofessional Communication: Standardizing clinical handoffs and consultations to ensure patient safety.

The SBAR Communication Model

Originally developed by the military and adapted by the aviation and healthcare industries, the SBAR tool provides a standardized, logical communication structure for critical clinical interactions, prescriber consults, and emergency telephone handoffs:

                           THE SBAR COMMUNICATION MODEL

   S ── SITUATION         • Identify yourself, your clinical location, and the patient.
                          • State the immediate, concise clinical problem or concern.
   ─────────────────────────────────────────────────────────────────────────────────
   B ── BACKGROUND        • State admission diagnosis, pertinent clinical history, and dates.
                          • Provide relevant baseline lab values, vitals, and current drugs.
   ─────────────────────────────────────────────────────────────────────────────────
   A ── ASSESSMENT        • Deliver your professional clinical analysis of the problem.
                          • Identify specific DTPs, drug interactions, or toxicity risks.
   ─────────────────────────────────────────────────────────────────────────────────
   R ── RECOMMENDATION    • State your specific, actionable, and evidence-based proposal.
                          • Detail exact drug names, doses, routes, and monitoring timelines.

Detailed Scripted SBAR Clinical Example:

• Situation (S): "Hello Dr. Henderson, this is Marcus from inpatient clinical pharmacy calling regarding Robert Tremblay in bed 304B on the surgical unit. I am calling because Mr. Tremblay has developed acute renal impairment and his piperacillin-tazobactam requires an immediate dose reduction to prevent neurotoxicity."
• Background (B): "Mr. Tremblay is a 72-year-old male admitted 4 days ago for a complicated intra-abdominal abscess. He was started on piperacillin-tazobactam 4.5 g IV every 6 hours. His baseline serum creatinine was 80 µmol/L (eGFR > 60 mL/min). This morning's bloodwork shows his serum creatinine has risen sharply to 210 µmol/L, yielding an estimated creatinine clearance of 22 mL/min. He has no documented beta-lactam allergies."
• Assessment (A): "My assessment is that Mr. Tremblay is experiencing acute kidney injury secondary to post-operative sepsis and vancomycin co-administration. Piperacillin-tazobactam is cleared renally; continuing full dosing of 4.5 g Q6H in severe renal impairment (CrCl < 30 mL/min) leads to profound drug accumulation, increasing his risk of severe neurotoxicity, encephalopathy, and myoclonus."
• Recommendation (R): "I recommend reducing piperacillin-tazobactam to 2.25 g IV every 6 hours, or converting to 3.375 g IV every 8 hours. In addition, I recommend repeating serum creatinine, BUN, and electrolytes in 24 hours, and checking his urine output Q4H. Would you like me to enter this dosage change under our hospital pharmacokinetic medical directive?"

---

Pharmacy Team Delegation, Workflow & Professional Boundaries

Pharmacy workflow in Canada relies on a clear division of responsibilities between Pharmacists, Registered Pharmacy Technicians (RPhTs), and Pharmacy Assistants. Understanding the precise legal and clinical boundaries of each role is essential for regulatory compliance and operational excellence.

Registered Pharmacy Technicians (RPhTs)

Across Canadian provinces, pharmacy technicians are regulated, licensed healthcare professionals governed by provincial regulatory authorities (e.g., Ontario College of Pharmacists, College of Pharmacists of BC, Alberta College of Pharmacy). RPhTs carry independent legal liability and professional accountability for the technical aspects of dispensing.

Authorized Scope of Practice for RPhTs:

• Independent Final Technical Verification: Performing the final product verification (the "technical check")—verifying that the physical drug, DIN, strength, dosage form, manufacturer, quantity, packaging, and auxiliary labels match the authorized prescription.
• Receiving Verbal Prescriptions: Authorized to accept verbal prescriptions from prescribers. Since October 1, 2026, the federal Controlled Substances Regulations also let technicians receive and record verbal prescriptions for controlled substances (s. 117), subject to provincial rules.
• Prescription Transfers: Transferring prescriptions to, or receiving transfers from, other pharmacies, including controlled-substance prescriptions within 2 years of receipt under CSR s. 102, where provincial rules allow.
• Best Possible Medication History (BPMH): Gathering the structured medication history from the patient and records, which the pharmacist then uses for the clinical assessment. PEBC's sample items treat BPMH collection as within the technician's role.
• Controlled-Substance Destruction and Records: Destroying controlled substances with a qualified witness and joint declaration (CSR s. 110), and keeping receipt and transfer records.
• Compounding Operations: Preparing, assembling, and performing final technical checks on non-sterile and sterile compounded preparations.
• Inventory & Supply Chain Oversight: Managing automated dispensing units (ADUs), narcotic safe reconciliation, and drug recall quarantine.

Pharmacists: Core Clinical Responsibilities

The pharmacist retains sole legal responsibility for the clinical / therapeutic check:

• Therapeutic Assessment: Evaluating whether the drug is indicated, therapeutically effective, safe, and clinically appropriate for the specific patient;
• Patient Consultation: Providing clinical education, discussing expectations, addressing ambivalence, and device training;
• Clinical Decision-Making: Prescribing for minor ailments, renewing prescriptions, adapting orders, initiating therapeutic substitutions, administering injections, and developing care plans.

Pharmacy Assistants (Unregulated Personnel)

Pharmacy assistants are unregulated team members who perform technical support functions under the direct supervision of an RPhT or pharmacist. They enter demographic data, count tablets, assemble blister packs, and process retail sales. They cannot perform independent technical checks or clinical evaluations.

                       PHARMACY DISPENSARY WORKFLOW DIVISION

      ROLE                     CORE RESPONSIBILITIES                 LEGAL BOUNDARIES
┌───────────────┬───────────────────────────────────────────────┬───────────────────────────────┐
│ PHARMACIST    │ • Clinical assessment & therapeutic check     │ • Full clinical scope         │
│               │ • Resolving DTPs & drug interactions          │ • Sole authority for clinical │
│               │ • Patient counselling & device training       │   counselling & prescribing   │
│               │ • Prescribing, adaptations & injections       │                               │
├───────────────┼───────────────────────────────────────────────┼───────────────────────────────┤
│ REGISTERED    │ • Independent final TECHNICAL verification    │ • NO clinical appropriateness │
│ PHARMACY TECH │ • Receiving verbal orders (incl. CSR drugs)   │   evaluations                 │
│ (RPhT)        │ • Prescription transfers                      │ • NO clinical counselling     │
│               │ • Compounding & product assembly              │ • NO therapeutic adaptations  │
├───────────────┼───────────────────────────────────────────────┼───────────────────────────────┤
│ PHARMACY      │ • Demographic & prescription data entry       │ • Unregulated support         │
│ ASSISTANT     │ • Counting, pouring & packaging tablets       │ • Must work under direct      │
│               │ • Inventory stocking & cashier operations     │   supervision of RPhT/Pharm   │
└───────────────┴───────────────────────────────────────────────┴───────────────────────────────┘

---

Resource Stewardship & Drug Shortage Management

Drug shortages represent a persistent vulnerability in the Canadian healthcare system, threatening patient safety and clinical continuity. Pharmacists serve as frontline stewards during national supply disruptions.

Health Canada Mandatory Reporting Framework

Under the Food and Drug Regulations, pharmaceutical manufacturers are legally mandated to report all anticipated and actual drug shortages and discontinuations on the national reporting website:

$\text{drugshortagescanada.ca}$

• Mandatory Reporting Timelines:
  • Anticipated Shortages: Must be posted at least 6 months in advance, or within 5 days of becoming aware of the anticipated shortage if 6 months' notice is impossible;
  • Actual Shortages: Must be posted within 5 days of becoming aware, if not already reported;
  • Updates and Resolution: Changes to a posted report, including the end of the shortage, must be updated within 2 days;
  • Discontinuations: Must be posted at least 6 months before the discontinuation, or within 5 days of the decision if that is not possible.

Shortage Tiers & Tier 3 Assignments

Health Canada categorizes shortages based on healthcare impact:

• Tier 1 & Tier 2 Shortages: Shortages with low to moderate clinical impact, where acceptable alternative formulations, therapeutic substitutions, or alternative manufacturers are readily accessible.
• Tier 3 Drug Shortages: National shortages with the highest potential impact on the Canadian health system. A Tier 3 shortage is declared when there is a severe shortage of a medically necessary drug for which no authorized alternative is available in sufficient quantity, posing an imminent and significant risk of serious patient harm or death. Tier 3 shortages are coordinated by Health Canada's Tier 3 Assignment Committee and the Multi-Stakeholder Steering Committee (MSSC) on Drug Shortages.

Clinical Management Strategies for Drug Shortages

When commercial products become unavailable, pharmacists operationalize four primary mitigation strategies:

                     DRUG SHORTAGE MITIGATION HIERARCHY

  1. THERAPEUTIC      Substitute equivalent chemical entity or therapeutic class agent
     SUBSTITUTION     using independent prescribing / adaptation scope or medical directive.
  ─────────────────────────────────────────────────────────────────────────────────
  2. EXTEMPORANEOUS   Compound liquid formulations or capsules from active pharmaceutical
     COMPOUNDING      ingredients (APIs) or commercial tablets under NAPRA standards.
  ─────────────────────────────────────────────────────────────────────────────────
  3. INVENTORY        Implement dispensing limits (e.g., maximum 30-day supplies) to
     RATIONING        prevent panic hoarding and ensure equitable community supply.
  ─────────────────────────────────────────────────────────────────────────────────
  4. EXCEPTIONAL      Dispense foreign-authorized alternatives imported by Health Canada
     IMPORTATION      under specialized interim orders with bilingual risk communications.

1. Therapeutic Substitution & Adaptation: Utilizing pharmacist independent prescribing or adaptation powers (under provincial legislation) to switch a patient to an equivalent therapeutic alternative (e.g., substituting cephalexin for amoxicillin during pediatric liquid shortages, or substituting oral semaglutide for subcutaneous GLP-1 shortages).
2. Extemporaneous Compounding: Compounding oral suspensions, pediatric liquids, or specialized dosage units from bulk active pharmaceutical ingredients (APIs) or commercial tablets in accordance with NAPRA Model Standards for Pharmacy Compounding of Non-sterile Preparations.
3. Inventory Rationing & Allocation Protocols: Restricting dispensing quantities to a 30-day supply (rather than 90-day fills) to prevent hoarding, protect vulnerable patients, and maintain equitable distribution across the population. In institutional settings, Tier 3 allocation protocols triage remaining supply strictly to high-acuity indications (e.g., intensive care, pediatrics, oncology).
4. Exceptional Importation & Sale: Under the Food and Drugs Act, Health Canada authorizes the exceptional importation and distribution of foreign-licensed drugs (e.g., products authorized by the US FDA or European Medicines Agency [EMA]). When dispensing foreign-sourced drugs, pharmacists must supply bilingual (English/French) supplementary clinical information sheets to explain differences in packaging, strength conventions, or preparation.

---

Formulary Management & Biosimilars Transition Initiatives

Biologic drugs (large, complex proteins derived from living cells) represent the fastest-growing expenditure in Canadian public drug programs. To ensure long-term healthcare sustainability, Canadian jurisdictions have instituted comprehensive biosimilar transition policies.

Science of Biosimilars: Health Canada Authorization Standards

According to Health Canada regulations, a biosimilar biologic drug is a biologic drug that is demonstrated to be highly similar to a brand-name reference biologic drug (innovator), with no clinically meaningful differences in efficacy, safety, and immunogenicity.

                      GENERIC VS. BIOSIMILAR COMPARISON

  ATTRIBUTE                SMALL-MOLECULE GENERIC         BIOSIMILAR BIOLOGIC
┌──────────────────────┬──────────────────────────────┬──────────────────────────────┐
│ Molecular Structure  │ Small, simple, chemically    │ Large, complex protein       │
│                      │ synthesized (e.g., ASA).     │ (e.g., monoclonal antibody). │
├──────────────────────┼──────────────────────────────┼──────────────────────────────┤
│ Manufacturing        │ Predictable chemical         │ Living cell cultures         │
│                      │ synthesis.                   │ (variable micro-heterogeneity│
│                      │                              │  such as glycosylation).     │
├──────────────────────┼──────────────────────────────┼──────────────────────────────┤
│ Identity Standard    │ Chemically IDENTICAL to      │ Highly SIMILAR to reference; │
│                      │ reference drug.              │ NO clinically meaningful     │
│                      │                              │ differences.                 │
├──────────────────────┼──────────────────────────────┼──────────────────────────────┤
│ Approval Pathway     │ Abbreviated New Drug Sub     │ Comprehensive comparability: │
│                      │ (ANDS) based on PK           │ Structural, functional, PK,  │
│                      │ bioequivalence (AUC/Cmax).   │ PD, and clinical safety/eff. │
└──────────────────────┴──────────────────────────────┴──────────────────────────────┘

• Totality-of-the-Evidence Approach: Unlike small-molecule generics, biosimilars cannot be chemically identical because living cell expression systems possess natural micro-heterogeneity. Approval requires extensive structural and functional characterization (physicochemical assays), animal toxicology, human pharmacokinetic/pharmacodynamic (PK/PD) studies, and clinical confirmatory trials demonstrating equivalent therapeutic response and lack of immunogenicity.

Provincial Biosimilar Switching Policies

Starting in 2019 with British Columbia and subsequently adopted by Alberta, Ontario, Quebec, Saskatchewan, New Brunswick, Nova Scotia, and Newfoundland and Labrador, provincial public drug plans implemented mandatory biosimilar switching policies:

• Policy Mandate: Patients covered under public drug benefit programs who receive originator biologics (e.g., Remicade [infliximab], Enbrel [etanercept], Humira [adalimumab], Lantus [insulin glargine], Copaxone [glatiramer]) are required to transition to an authorized biosimilar version within a specified transition window (typically 6 months) to maintain public reimbursement.
• Exemptions: Medically justified exemptions (e.g., pregnancy, pediatric patients nearing transition, documented clinical hypersensitivity to specific non-medicinal excipients) require formal prescriber exemption requests.

The Nocebo Effect & Pharmacist Communication Strategies

A central clinical hurdle in biosimilar transitions is the nocebo effect—a phenomenon where a patient experiences subjective adverse effects or perceived loss of clinical efficacy driven entirely by negative expectations, anxiety, or lack of confidence in the biosimilar, rather than any physiological drug action.

---

Clinical Case Scenario: Managing an Inpatient Drug Shortage Using SBAR & RPhT Collaboration

A regional tertiary hospital faces a critical national Tier 3 shortage of intravenous metronidazole 500 mg/100 mL piggyback bags. The surgical ward has 6 patients currently receiving IV metronidazole for polymicrobial intra-abdominal infections, but the central pharmacy has only 4 bags remaining in stock. The clinical pharmacist and the lead Registered Pharmacy Technician collaborate to resolve the crisis.

Step-by-Step Interprofessional Response:

1. Technician Inventory Audit & Physical Quarantine: The RPhT immediately runs an inventory query across all automated dispensing units (Pyxis/Omnicell), consolidates the remaining 4 IV bags into the central pharmacy sterile compounding cleanroom, and places a technical lock in the electronic health record to prevent unauthorized floor-stock dispensing.
2. Pharmacist Clinical Patient Assessment: The pharmacist reviews all 6 surgical patients. Four of the patients are tolerating oral intake and have functional gastrointestinal tracts (diet advanced to solids/liquids). Two patients are strictly NPO (nothing by mouth) with active bowel obstruction.
3. Pharmacist Step-Down / IV-to-Oral Conversion: Oral metronidazole exhibits near 100% oral bioavailability, achieving serum concentrations virtually indistinguishable from intravenous administration. The pharmacist executes an IV-to-oral step-down under the hospital's Clinical Pharmacy Medical Directive for the 4 patients tolerating oral intake, converting them to oral Metronidazole 500 mg tablets TID.
4. SBAR Communication with Attending Surgeon: For the two NPO patients, the remaining 4 IV bags provide only a 24-hour supply. The pharmacist contacts the attending surgical team using SBAR to recommend transitioning to IV Moxifloxacin 400 mg once daily or IV Piperacillin-tazobactam 3.375 g Q6H (providing anaerobic coverage) once the metronidazole bags are exhausted.
5. Documentation & Stewardship Audit: The pharmacist documents all interventions in the medical charts, files a shortage impact report with the hospital Pharmacy and Therapeutics (P&T) Committee, and logs the clinical resolution.